Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81–6.

Article  PubMed  Google Scholar 

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luchini C, Lawlor RT, Milella M, Scarpa A. Molecular tumor boards in clinical practice. Trends Cancer. 2020;6(9):738–44.

Article  PubMed  Google Scholar 

Wang C-Y, Wei L-Q, Niu H-Z, Gao W-Q, Wang T, Chen S-J. Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. World J Gastroenterol. 2018;24(39):4482.

Article  PubMed  PubMed Central  Google Scholar 

Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53.

Article  PubMed  PubMed Central  Google Scholar 

Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15(5):386–94.

Article  CAS  PubMed  Google Scholar 

Delgado A, Guddati AK. Clinical endpoints in oncology-a primer. Am J cancer Res. 2021;11(4):1121.

PubMed  PubMed Central  Google Scholar 

Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F et al. Evolving Landscape of molecular prescreening strategies for oncology early clinical trials. JCO Precis Oncol. 2020;4.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Schwartz LH, Litière S, De Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.

Article  PubMed  PubMed Central  Google Scholar 

Feinberg BA, Zettler ME, Klink AJ, Lee CH, Gajra A, Kish JK. Comparison of solid tumor treatment response observed in clinical practice with response reported in clinical trials. JAMA Netw Open. 2021;4(2):e2036741–e.

Article  PubMed  PubMed Central  Google Scholar 

Paesmans M, Sculier J, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European lung cancer working party. Eur J Cancer. 1997;33(14):2326–32.

Article  CAS  PubMed  Google Scholar 

Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res. 2005;11(16):5928–34.

Article  PubMed  Google Scholar 

El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26(8):1346–54.

Article  PubMed  Google Scholar 

Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005–2022. J Cancer Policy. 2022;34:100364.

Article  PubMed  Google Scholar 

Shahnam A, Hitchen N, Nindra U, Manoharan S, Desai J, Tran B, et al. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer. 2024;198:113503.

Article  PubMed  Google Scholar 

Li L, Pan Z. Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials. Clin Breast Cancer. 2018;18(1):63–70.

Article  PubMed  Google Scholar 

Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(3):311–7.

Article  PubMed  Google Scholar 

Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück H-J et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. 2008.

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120–31.

Article  PubMed  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1.

Article  CAS  PubMed  Google Scholar 

Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Rühlmann K, Flach M, et al. Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) molecular tumor board. J Cancer Res Clin Oncol. 2023;149(5):1905–15.

Article  PubMed  Google Scholar 

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1–Standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer. 2016;62:138–45.

Article  PubMed  PubMed Central  Google Scholar 

Pannu HK, Bristow RE, Montz FJ, Fishman EK. Multidetector CT of peritoneal carcinomatosis from ovarian cancer. Radiographics. 2003;23(3):687–701.

Article  PubMed  Google Scholar 

D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808.

Article  PubMed  PubMed Central  Google Scholar 

Kok P-S, Yoon W-H, Lord S, Marschner I, Friedlander M, Lee CK. Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JCO Precision Oncol. 2021;5:1151–9.

Article  Google Scholar 

Feinberg BA, Bharmal M, Klink AJ, Nabhan C, Phatak H. Using response evaluation criteria in solid tumors in real-world evidence cancer research. Future Oncol. 2018;14(27):2841–8.

Article  CAS  PubMed  Google Scholar 

Charara RN, Kreidieh FY, Farhat RA, Al-Feghali KA, Khoury KE, Haydar A, et al. Practice and impact of multidisciplinary tumor boards on patient management: a prospective study. J Global Oncol. 2017;3(3):242–9.

Article  Google Scholar 

Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? The lancet oncology. 2006;7(11):935–43.

Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ. The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer. 2006;42(15):2459–62.

Article  PubMed  Google Scholar 

Beets G, Sebag-Montefiore D, Andritsch E, Arnold D, Beishon M, Crul M, et al. ECCO essential requirements for quality cancer care: colorectal cancer. A critical review. Crit Rev Oncol/Hematol. 2017;110:81–93.

Article  PubMed  Google Scholar 

Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2023;189(1):G1–42.

Article  PubMed  Google Scholar 

Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, et al. ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review. Crit Rev Oncol/Hematol. 2017;110:94–105.

Article  PubMed  Google Scholar 

Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, et al. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. Crit Rev Oncol/Hematol. 2018;122:179–93.

Article  PubMed  Google Scholar 

Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H, et al. ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol/Hematol. 2020;148:102861.

Article  PubMed